Loading organizations...
§ Private Profile · Durham, NC, USA
Biotechnology company developing the Codetta Platform, a multi-omics solution for life sciences research and diagnostic development.
Codetta Bio has raised $15.0M across 1 funding round.
Key people at Codetta Bio.
Codetta Bio has raised $15.0M in total across 1 funding round.
Based in Morrisville, North Carolina, Codetta Bio develops a fully integrated multi-omics platform to detect multiple protein and nucleic acid analytes from a single sample for life sciences research and diagnostic development. National Academy of Engineering member Michael Ramsey founded the biotechnology company in 2021 using core technology that originated at UNC-Chapel Hill and was initially inspired by a DARPA broad agency announcement. Commercialization efforts are currently led by Chief Executive Officer Jacques Corriveau, an industry veteran with over 25 years of life sciences experience appointed in October 2023. To date, the enterprise has secured $16,600,000 in total funding across three rounds, reaching an estimated valuation of $3,900,000. Operating with a workforce of 21 to 50 employees, the organization generates an estimated $1,200,000 in annual revenue by providing these revolutionary multi-omics tools to scientists.
Codetta Bio is a biotechnology company founded in 2021 that develops advanced multi-omics biomarker measurement tools, focusing on a fully integrated platform for simultaneous DNA, RNA, and protein analysis from a single sample.[1][2][3][5] Its Concerto System combines digital PCR, real-time PCR, and immunoPCR technologies on a single instrument, enabling high-sensitivity, high-throughput multiplexing in just a 3-hour run, primarily serving translational research, clinical trials, and diagnostic development.[1][2][5] The company has raised $17.26M in funding, reaching Series A-II stage, with its Mosaic Score rising +129 points recently, signaling strong market potential.[1]
Codetta Bio emerged in 2021 from the vision of co-founder Michael Ramsey, a National Academy of Engineering member with over 300 peer-reviewed papers, 165 issued patents, and expertise in microfluidics and chemical analysis.[3] Ramsey's background in pioneering optical and analytical technologies laid the groundwork for the company's innovative platform, driven by the need for optimal sensitivity and efficiency in biomarker detection from limited samples.[3] Early traction built on this foundation, with the company basing operations in Morrisville/Durham, North Carolina, and securing $17.26M in funding, including a $2.26M round 8 months ago, amid leadership additions like strategic experts in corporate strategy and genomics.[1][2]
Codetta Bio rides the multi-omics revolution in precision medicine, where integrating genomic, transcriptomic, and proteomic data from single samples accelerates biomarker discovery for clinical trials and personalized diagnostics.[1][3][5] Timing aligns with surging demand for scalable, cost-effective tools amid NGS limitations in plexing and throughput, fueled by market forces like rising clinical trial complexity and wellness-focused research on genetic/environmental factors.[1][4] By enabling easier multiplexing, it influences the ecosystem, potentially standardizing multi-omics in labs and fine-tuning patient selection, bridging research-to-clinic gaps.[1][3]
Codetta Bio is poised to commercialize its Concerto System, expanding into broader diagnostic adoption as multi-omics matures.[1][4][5] Trends like AI-driven analytics and single-sample efficiency will amplify its edge, with recent funding and leadership bolstering scale-up.[1] Its influence may evolve into an industry standard for biomarker tools, harmonizing data like a codetta in biotech's symphony, empowering precision health breakthroughs.[3][5]
Codetta Bio has raised $15.0M in total across 1 funding round.
Codetta Bio's investors include Anzu Partners, Parag Jhaveri, Genoa Ventures, VC23.
Codetta Bio has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Series A in April 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2022 | $15M Series A | Anzu Partners | Parag Jhaveri, Genoa Ventures, VC23 | Announced |
Key people at Codetta Bio.
